MicroPort 心通医疗



MicroPort CardioFlow Medtech Corporation

2021 Interim Results Presentation

August 2021

Disclaimer

This presentation has been prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the "Company") solely for use of 2021 interim results presentation.

The information contained in this presentation has not been reviewed by any regulatory authority in any jurisdiction nor independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alternations, modifications or changes.

This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as "expects," "plan," "will," "estimates," "projects," "intends," or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward- looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information.

This presentation is highly confidential, is being presented solely for your information and for your use and may not be copied, reproduced or redistributed to any other person in any manner without the Company's prior written consent. Unauthorized copying, reproduction or redistribution of this presentation could be limited or prohibited by the securities laws of various jurisdictions. By attending this presentation, you are agreeing to maintain absolute confidentiality regarding the information contained in this presentation and to be bound by the restrictions and other limitations set forth herein. Any failure to comply with these limitations may constitute a violation of law and may lead to legal or regulatory action.

This presentation is for information purposes only and does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

No securities of the Company may be offered, sold or transferred within the United States or to, or for the account or benefit of U.S. persons, without registration with the United States Securities and Exchange Commission, except as pursuant to an exemption from, or in a transaction not subject to, such registration requirements. The Company has not registered and does not intend to register any securities of the Company under the U.S. Securities Act of 1933, as amended. There will be no public offering of any securities by the Company in the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the Offering for subscription of such shares has been formally approved by The Stock Exchange of Hong Kong Limited in accordance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) and duly registered by the Registrar of Companies in Hong Kong. The securities referred to herein have not been and will not be registered under the applicable securities laws of the People's Republic of China (the "PRC"), and may not be offered or sold within the PRC or to any national, resident or citizen of the PRC.

This document does not constitute a prospectus or an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong and may only be made available to professional investors within the meaning of the Securities and Futures Ordinance of Hong Kong. The receipt of this document by any recipient is not to be taken as constituting the receipt of investment advice or an establishment of customer or client relationship.
By attending this presentation, participants agree not to remove this presentation, or any materials provided in connection herewith, from the conference room or online platform where such presentation or materials are provided. Participants agree further not to photograph, copy or otherwise reproduce these materials during the presentation or while in the conferenceroom. Participants must return this presentation and all other materials provided in connection herewith to the Company at the completion of the presentation.

Agenda

Business Highlights

Fast-Growing Market Share

- Extensive nationwide coverage in 29 out of 34 provinces
- VitaFlow® has been performed at 220 hospitals，↑53% (No.1 in approx. 100 hospitals)
- Covered 19 out of Top 20 hospitals (market leading position in 10 hospitals)
- Initiated collaboration with MicroPort's cardiovascular team to facilitate patient recommendation

Solid R&D Progress

TAVI

- VitaFlow Liberty™ (2nd generation) obtained NMPA approval in August
- Angelguide® tip pre-shaped super stiff guidewire obtained NMPA approval in August
- Alwide® Plus Balloon Catheter obtained NMPA approval in July
- VitaFlow™ III (self-expanding): new size design ongoing; fatigue test cycles reach new high

TMV

- Self-developed replacement product: completed chronic animal study with 90-days follow ups which demonstrated positive results; design frozen; compassionate procedure use by the end of 2021
- Amend (repair): completed 4 trans-septal cases, showing significant MR reduction; China compassionate procedure use under preparation
- Altavalve (replacement): early human feasibility study; initiate China compassionate procedure use by 2021
- Corona (replacement): animal studies

Overseas Expansion

- First overseas implantation in Argentina in August 2021
- VitaFlow Liberty™: the only China-developed product to conduct clinical trial in EU, expected to submit CE application by 2021 end and obtain CE Mark in 2022
- Leverage on MicroPort's brand recognition worldwide and overseas sales network
- Collaborate with global enablers, including medical device companies, research institutes, hospitals, KOLs and distributors, to advance our international strategy

Sales & Marketing Review

Rapid Penetration into Hospitals and Increased Market Share in China

Extensive coverage in China market with presence in **29** provinces and **No.1** market share in **5** provinces



Provinces penetrated successfully

Provinces with No.1 market share

Top 20 TAVI hospitals: penetrated successfully

Top 20 TAVI hospitals: On-going negotiation for penetration

VitaFlow® has been performed at **220** hospitals[1], ↑**76** hospitals[2] ↑ **53%**

144 exclusive hospitals/departments

No.1 market share in approx. **100** hospitals

Penetrated **19** of Top 20 TAVI Hospitals[1]

Market leading position in **10** of Top 20 hospitals

Won the **exclusive bid** of medical reimbursement in Yunnan and Guizhou

Note: [1] As of June 30, 2021 [2]compared with data as of 31 Dec 2020

Top 20 TAVI hospitals are expected to perform the most TAVI procedures in China in 2020, according to Frost & Sullivan. The 20 hospitals include 1. West China Hospital of Sichuan University (四川大学华西医院); 2. The First Affiliated Hospital of Air Force Medical University (Xijing Hospital) (空军军医大学第一附属医院(西京医院)); 3. Fuwai Hospital of Chinese Academy of Medical Sciences (中国医学科学院阜外医院); 4. Zhongshan Hospital, Fudan University (复旦大学附属中山医院); 5. The Second Affiliated Hospital of Zhejiang University School of Medicine, (浙江大学医学院附属第二医院); 6. Beijing Anzhen Hospital, Capital Medical University (首都医科大学附属北京安贞医院); 7. Guangdong General Hospital (广东省人民医院); 8. Wuhan Asia Heart Hospital (武汉亚洲心脏病医院); 9. Tianjin Chest Hospital (天津市胸科医院); 10. The Affiliated Hospital of Qingdao University (青岛大学附属医院); 11. Changhai Hospital of Shanghai (上海长海医院); 12. Sir Run Run Shaw Hospital,Zhejiang University School of Medicine (浙江大学医学院附属邵逸夫医院); 13. The First Affiliated Hospital of Zhengzhou University (郑州大学第一附属医院); 14. Fuwai Central China Cardiovascular Hospital (阜外华中心血管病医院); 15. Fujian Medical University Union Hospital (福建医科大学附属协和 医院); 16. The First Affiliated Hospital of Zhejiang University School of Medicine (浙江大学医学院附属第一医院); 17. The Second Affiliated Hospital of Army Medical University of PLA (Xinqiao University) (解放军陆军军医大学第二附属医院(新桥医院)); 18. Nanjing First Hospital (南京市第一医院); 19. The First Hospital of Lanzhou University (兰州大学第一医院); 20. Henan Provincial Chest Hospital (河南省胸科医院)

Academic Promotion to Explore and Penetrate New Hospitals in China

Approx. **110** physicians can independently perform TAVI procedures

Approx. **90** physicians can independently perform VitaFlow®, **↑80%** *(compared to 2020 end)*

Attended 38 academic conferences including OCC and China Valve



Launched 33 academic seminars including 11 national seminars

Initiated 23 training activities

1000+ doctor attendees

Initiated long-term marketing program
"VitaFlow® elite competition"

- *To train more physicians to independently perform VitaFlow™ procedures*

- *To standardize VitaFlow® procedures*



- *To enhance brand recognition*

Clear Roadmap to Penetrate International Markets

- VitaFlow® completed its **first overseas commercial implantation** in Argentina
- VitaFlow Liberty™ being the **only China-developed TAVI product commenced clinical trial in EU** , expected to **obtain CE Mark in 2022**
- Leverage on **MicroPort Group's extensive overseas network** to accelerate commercialization

3 VitaFlow Liberty™

- ✓ **Obtained NMPA approval** in August
- ✓ Conducting a pivotal clinical trial for VitaFlow Liberty™ **in Europe** for **CE Mark registration**
- ✓ Seeking product registrations in **emerging markets,** especially countries that recognize **CE Mark or the NMPA approval**



2 VitaFlow®

- ✓ Successfully registered in Argentina and Thailand
- ✓ **Completed first case in Argentina in August**
- ✓ Seeking product registrations in **emerging markets,** especially countries that recognize **NMPA approval**

1 VitaFlow®

- ✓ **NMPA approval** in China in 2019
  - The pivotal clinical trial for VitaFlow® took only eleven months from the first patient enrollment to completing TAVI procedures on all the patients

CE marking | NMPA approval or CE marking | NMPA approval or CE mark | CE mark

Product Pipeline Update

Comprehensive, innovative and high-quality transcatheter and surgical solutions for structural heart diseases



TAVI

- Total TAVI solution provider
- VitaFlow Liberty™ obtained NMPA in Aug
- Clinical data shows excellent safety and efficacy
- VitaFlow™ III: design frozen by 2021 end
- Balloon-expandable VitaFlow™: design stage; tap into the new market

TMV

- 5 products in pipeline, covering both replacement and repair technology
- 2 in-house developed products
- Collaboration with global partners Valcare and 4C Medical



Procedural Accessories

- 3 products launched; 5 under R&D
- The only company in China with comprehensive in-house developed procedural accessories
- Lower the challenges and shorten learning curve for physicians

Surgical Valve

- Design to be frozen by 2021 end
- Leverage on our existing network with surgical teams at various hospitals

TTV

- In-house developed edge-to-edge repair product is at design stage
- Collaborate with global partner Valcare to develop Trivid repair product, currently at design stage

Note: Please refer to Appendix 1 for overview of product pipeline.

R&D Update and Outlook

	Product	Status as at 31 Dec 2020	Progress in 2021 1H	Next milestone	Expected approval time
Aortic valve products	VitaFlow Liberty™ (Retrievable) NMPA	NMPA application accepted	Completed submission of supplementary information	Launch in September	Obtained NMPA approval in August ★
	VitaFlow Liberty™ (Retrievable) CE	Clinical trial in Europe	Design confirmed/transfer	Submitted CE application by the end of 2021	Dec. 2022
	VitaFlow™ III NMPA	Design stage	Follow-up of animal test data	Design frozen by end of 2021	Dec. 2025
Mitral valve products	Self-developed edge-to-edge repair	Design stage	Design confirmed	Design frozen by end of 2021	Dec. 2025
	Amend	One TA implantation	Four TA implantation	China Compassionate procedure in 1H 2022	/
	Self-developed TMV replacement	Long-term follow-up of animal test data	Design frozen	Compassionate procedure by the end of 2021	June. 2026
	Alta Valve	Design frozen	Early human feasibility study	China Compassionate procedure by end of 2021	/
Procedural accessories	Catheter Sheath NMPA	Verification stage	Design frozen	Submit for NMPA approval in Feb. 2022	Dec. 2022
	Balloon catheter III NMPA	Verification stage	Design fixed, under verification	Submit for NMPA approval in April. 2022	April. 2023
	Angelguide® tip pre-shaped super stiff guidewire	NMPA application accepted	Completed submission of supplementary information	Launch in September	Obtained NMPA approval in August ★
	Embolic protection device	JV established	Design frozen	Launched multi-center clinical trial	Dec. 2024
Surgical valve product	Surgical valve	Design stage	Design confirmed	Design frozen by the end of 2021	Dec. 2025

TAVI Products – Total Solution Provider for TAVI Procedures

MicroPort 心通医疗

TAVI families



- **Strong R&D capabilities** to develop all TAVI products in house
- **Solid R&D progress** in 2021 1H and further enrichment of TAVI solutions
  - ➢ **VitaFlow Liberty™ obtained NMPA approval in August**
  - ➢ **Angelguide® tip pre-shaped super stiff guidewire obtained NMPA approval in August**
  - ➢ **Alwide® Plus Balloon Catheter obtained NMPA approval in July**
- The **only company in China** that offers a comprehensive portfolio of self-developed TAVI procedural accessories

4 Aortic Valve Products

- 1 commercialized
- 1 approved
- 2 under R&D

8 Procedural accessories

- 2 commercialized
- 1 approved
- 5 under R&D

Product	R&D stage	Properties / Progress
VitaFlow™III Self-Expanding	■ Design to be frozen	■ New size design ongoing ■ Fatigue test cycles reach new high ■ Long term animal study in preparation
VitaFlow™ Balloon Expandable	■ Design stage	■ Prototype received, evaluation undergoing ■ New design ongoing
Alwide™ balloon catheter III	■ Design fixed, under verification	■ Type test ongoing ■ Shelf life verification ongoing ■ Product verification ongoing ■ Production process validation ongoing
Alpass™ catheter sheath II	■ Design fixed, under verification	■ Improved lubricity with various models available
Expandable sheath	■ Design stage	■ Reducing access complications
Embolic Protection Device	■ Design frozen	■ To protect the brain during TAVI procedures

TAVI Products - Positive Clinical Trial Results

VitaFlow®

Valve Transcatheter Aortic Valve Implantation System



1-year follow-up period

0 moderate or severe PVL

2-year follow-up period

0 major (disabling) stroke

All-cause mortality rate: **relatively lower**

	VitaFlow®	Peer
30 days	**0.9%**	5%
1-year	**2.7%**	5.9%
2-year	**4.5%**	8.9%
3-year	**10.9%**	12.9%
4-year	**12.7%**	14.9%

Please refer to Appendix 2 for full comparison data of clinical trial results.

VitaFlow Liberty™ (2nd Generation)

Valve Transcatheter Aortic Valve Implantation System



30-day follow-up period

0 major (disabling) stroke

Significantly improved cardiac functions

*NYHA Classification**

	Before	*30-day follow-up*
Class I (%)	0	**19.3%**
Class II (%)	18.3%	**68.4%**

Note*: New York Heart Association Functional Classification, a simple way of classifying the extent of heart failure provided by the New York Heart Association. It classifies patients in one of four categories based on their limitations during physical activity, in regards to normal breathing and varying degrees in shortness of breath and/or angina pain

TMV Products

Robust Pipeline Covering All Mainstream Viable TVT Options of Mitral Regurgitation

TMV repair	TMV repair product	In-house development	Design confirmed	An edge-to-edge product which will adopt a transseptal approach Prototype received, evaluation undergoing
	Amend	Partnership with Valcare	Early Feasibility Study Strategy for regulatory pathway: apply for FDA breakthrough designation Trans-septal system developed	Innovative ring design with unique anchoring capabilities Maintain original mitral valve's structural integrity for long-term performance improvement Compatible with both transeptal or transapical approaches Four trans-septal cases successfully completed, which demonstrated unique features and enabling annular resizing and MR reduction
TMV replacement	TMV replacement product	In-house development	Completed animal study Design frozen	Reduce the risks of LVOT obstruction Thin diameter of 32 Fr which cause less damage while preserving the ventricle function Less vascular damage during delivery Compassionate use in preparation
	Corona	Partnership with Valcare	Animal studies	Valve-in-ring solution for TMV repair ineligible patients Unique four-leaflet valve design to improve cooptation and sealing efficacy
	AltaValve	Partnership with 4C Medical	Early Feasibility Study	Supra-annular fit and atrial-only fixation design to overcome the concerns of anchoring and fixation difficulties Reduce the risks of LVOT obstruction and damage Suitable for the vast majority of patients suffering from MR China Compassionate use approved by EC of Shanghai Zhongshan Hospital in March Introduced TA approach into China compassionate study protocol to accelerate case enrollment

Financial Review

Strong Revenue Growth

The Company's **revenue increased by 122% YOY in 2021 1H**. Sales volume increased by 120% in 2021 1H compared to 2020 1H, with relatively stable average unit sales price

Revenue
(RMB'000)



Volume
(Unit)



Revenue Growth Drivers

- **Overall China TAVI Market Growth**
- **Expansion of Eligible Hospital**

Successful Hospital Penetration

- As of 30 June, 2021, TAVI procedures using VitaFlow® had been performed at 220 hospitals in China, including 19 of the Top 20 TAVI Hospitals

Sharp Gross Profit Growth and Margin Expansion

The Company's **gross profit and gross profit margin expanded sharply in 2021 1H** due to strengthened bargaining power better cost control and improved manufacturing efficiency.

Cost of sales

(RMB'000)



Gross profit and gross profit margin

(RMB'000/%)



Gross profit margin expansion driven by:

- **Higher bargaining power** against raw material suppliers;
- **Reduced unit raw material cost** through further exploration and negotiation with suppliers for key raw materials;
- **Reduced unit manufacturing costs** with economies of scale
- **Continuous improvement of production efficiency;**

Improved Operating Profitability

We have seen **significant improvement in the operating profitability** with the percentage of operating expense as of revenue reduced from 178% in 2020 1H to 119% in 2021 1H as illustrated below.

R&D Expenses

(RMB'000)

% of revenue[1] 78% 57%

- More R&D projects on-going resulting in significant increase in R&D expenses.



Distribution Costs

(RMB'000)

46% 46%

- Increased marketing activities along with the enhanced market recognition of VitaFlow® resulting in significant increase in distribution costs



Administrative Expenses

(RMB'000)

53% 16%

- Relatively stable administrative expenses excluding the share-based compensation expenses



Share-based compensation expenses

Note:[1] Excluded share-based compensation expenses

Appendix

Appendix 1: Overview of Product Pipeline

Product			Pre-clinical	Clinical trial	Registration
Aortic valve products	VitaFlow® System	VitaFlow® ●	Launched (NMPA Green Path)		
			Successfully registered in Argentina and Thailand		
		Alwide® balloon catheter*	Launched		
			Successfully registered in Argentina and Thailand		
		Alpass® catheter sheath* ▲	Launched		
			Successfully registered in Argentina		
	VitaFlow Liberty™ System	VitaFlow Liberty™ *(Retrievable)* ★	obtained NMPA approval in August		
			CE Marking: Clinical trial in progress Registration in Brazil in progress		
		Angelguide® tip-preshaped super stiff guidewire* ▲	obtained NMPA approval in August		
	VitaFlow™ III	VitaFlow™ III *(Maintain coronary access and new anti-calcification technology)*	Design fixing		
	VitaFlow™ Balloon Expandable	VitaFlow™ Balloon Expandable *(New anti-calcification technology)*	Design stage		
Mitral valve products	In-house-developed replacement product		Animals studies		
	AltaValve – Innovative replacement product *(Partnership with 4C Medical – commercialization rights in China)*		Early feasibility study		
	Corona – Replacement product *(Partnership with Valcare – commercialization rights in China)*		Animal studies		
	In-house-developed Edge to Edge – Repair product		Design fixed		
	Amend – Repair product *(Partnership with Valcare – commercialization rights in China)*		FIH clinical trial in process with four completed implantations		
Tricuspid valve products	Trivid – Repair product *(Partnership with Valcare – commercialization rights in China)*		Design stage		
	Edge to Edge – Repair product		Design stage		
Surgical valve product	Surgical replacement product		Design fixing		
Procedural accessories	Alwide™ plus balloon catheter ■		Launched		
	Alwide™ balloon catheter III ■		Verification stage		
	Alpass™ catheter sheath II ▲		Verification stage		
	Expandable sheath ▲		Design stage		
	Embolic Protection Device		Design stage		

China status Global status ★ Core products ● Key product

■ Applied or plan to apply for exemption from clinical trial for NMPA approval following relevant PRC regulations

▲ Among our product candidates, these devices are exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《免於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended

✱ These procedural accessories are registered and commercialized offered as part of VitaFlow™ or VitaFlow Liberty™ system and are not registered as standalone product in China

Appendix 2: TAVI Products - Clinical Data Comparison

Company	Product	30-days mortality rate[1]	30-days major (disabling) stroke[1]	1-year mortality rate[1]	1-year major (disabling) stroke[1]	1-year moderate to severe PVL rate	1-year major vascular complications	2-year mortality rate[1]	2-year major (disabling) stroke[1]	3-year mortality rate[1]	3-year major (disabling) stroke[1]	4-year mortality rate	4-year major (disabling) stroke
MicroPort 心通医疗	VitaFlow®	0.9%	0.0%	2.7%	0.0%	0.0%	2.7%	4.5%	0.0%	10.9%	1.8%	12.7%	2.0%
	VitaFlow Liberty™	5.0%	0.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
启明医疗 VENUSMEDTECH	VenusA-Valve	5.0%	1.0%	5.9%	1.0%	4.2%	5.9%	8.9%	1.0%	12.9%	1.0%	14.9%	N/A
	VenusA-Plus	4.8%	1.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
苏州杰成医疗 Suzhou Jiecheng Medical	J-Valve	4.7%	0.0%	5.6%	2.0%	1.1%	N/A	9.1%	2.0%	10.8%	N/A	N/A	N/A
Edwards	SAPIEN 3 (U.S. Trial)	2.2%	0.9%*	14.4%	2.4%*	2.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	SAPIEN 3 (China Trial)	0.0%	2.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PEIJIA 沛嘉医疗	TaurusOne	1.7%	N/A	6.7%	N/A	1.0%	4.2%	N/A	N/A	N/A	N/A	N/A	N/A
	TaurusElite	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: [1] The data is from pivotal clinical trial of corresponding products and not head-to-head clinical results. VitaFlow® (N=110), VitaFlow Liberty™ (N=60) VenusA-Valve (N=101), VenusA-Plus (N=62), J-Valve (N=107), TaurusOne (N=120), SAPIEN 3 China trial (N=50), U.S. trial (N=583)
*: The data marked with * represent the incidences of disabling stroke

Consolidated Income Statement

Unit: RMB'000	For the period ended June 30, 2021	For the period ended June 30, 2020	*Var.*
Revenue	86,193	38,859	122%
Cost of sales	-38,682	-21,723	78%
Gross profit	47,511	17,136	177%
Other net income	8,366	1,357	517%
Research and development costs	-48,998	-30,323	62%
Distribution costs	-39,475	-18,049	119%
Administrative expenses	-13,884	-20,660	-33%
Fair value changes in financial instruments	-655	-1,138	-42%
Other operating costs	-5,262	-17,102	-69%
Loss from operations	-52,397	-68,779	-24%
Finance costs	-17,057	-53,017	-68%
Share of profits of a joint venture	-112	-	n.a
Loss before taxation	-69,566	-121,796	-43%
Income tax	-499	-	n.a
Loss for the period and attributable to equity shareholders of the Company	-70,065	-121,796	-42%

Consolidated Balance Sheet

Unit: RMB'000	June 30, 2021	Dec 31, 2020	*Var.*
Non-current assets			
Property, plant and equipment	92,132	68,122	35%
Intangible assets	242,427	234,168	4%
Interest in a joint venture	33,567	34,007	-1%
Other financial assets	86,523	49,508	75%
Other non-current assets	31,975	6,408	399%
Total Non-current assets	**486,624**	**392,213**	**24%**
Current assets			
Inventories	64,600	67,769	-5%
Trade and other receivables	55,755	39,400	42%
Pledged and time deposits	325	325	0%
Cash and cash equivalents	2,775,793	612,474	353%
Total current assets	**2,896,473**	**719,968**	**302%**
Current liabilities			
Trade and other payables	84,211	86,059	-2%
Contract liabilities	23	-	n.a
Lease liabilities	8,871	7,202	23%
Derivative financial liabilities	326	60,371	-99%
Other financial liabilities	-	1,278,062	-100%
Total current liabilities	**93,431**	**1,431,694**	**-93%**
Net current liabilities	**2,803,042**	**-711,726**	**-494%**

Consolidated Balance Sheet

Unit: RMB'000	June 30, 2021	Dec 31, 2020	*Var.*
Non-current liabilities			
Lease liabilities	5,190	8,625	-40%
Deferred income	3,560	3,390	5%
Derivative financial liabilities	12,973	13,656	-5%
Total non-current liabilities	**21,723**	**25,671**	**-15%**
CAPITAL AND RESERVES			
Share capital	83	60	38%
Reserves	3,267,860	-345,244	-1047%
TOTAL EQUITY/(DEFICIT)	**3,267,943**	**-345,184**	**-1047%**

Consolidated Cash Flow Statement

Unit: RMB'000	For the period ended June 30, 2021	For the period ended June 30, 2020	*Var.*
Net cash used in operating activities	-44,334	-63,996	-31%
Net cash used in investing activities	-67,942	-9,789	594%
Net cash generated from financing activities	2,282,857	681,084	235%
Net cash increase in cash and cash equivalents	2,170,581	607,299	257%
Cash and cash equivalents at 1 January	612,474	109,263	461%
Effect of foreign exchange rate changes	-7,262	5,173	-240%
Cash and cash equivalents at 31 December	**2,775,793**	**721,735**	285%

Our mission

To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases

Optimal

Affordable